SYNCORE BIOTECHNOLOGY CO., LTD.

ACTIVE

No. 84, Zhongshan Rd., 台湾 Taipei, 台湾省, Taiwanwww.syncorebio.comPublicEstablished: 2008-01-01

Clinical Trials

2 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2008

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

37.5%

Phase 2

25.0%

Phase 3

25.0%

Trial Status Distribution

Active, not recruiting

25.0%

Completed

25.0%

No Longer Available

12.5%

Suspended

12.5%

Terminated

25.0%

Clinical Trials

Trials sponsored by this organization (8)

EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX

Phase 3

Completed

interventional

Oct 2018218 participants

Treatment for Metastatic Adenocarcinoma of the Pancreas

Phase 1

Active, not recruiting

Jun 2018218 participants

Treatment for Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas

Phase 1

Active, not recruiting

Apr 2018218 participants

To Evaluate the Efficacy and Safety of SCB01A in Subjects With r/m Squamous Cell Head and Neck Cancer

Phase 2

Terminated

interventional

Apr 201710 participants

A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer

Phase 3

Suspended

interventional

Nov 2016420 participants

Study of SCB01A in Patient With Head and Neck Cancer

Phase 2

Terminated

interventional

Sep 20155 participants

A Dose Escalation Study of SCB01A in Subjects With Advanced Solid Tumors Who Have Failed Standard Therapy

Phase 1

Completed

interventional

Apr 201133 participants

Long-Term Compassionate Use Study for Continued Administration of SCB01A-01

No Longer Available

expanded access

Approvals

No approval data available

News

No news articles found

Back to Organizations